#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hodgkin's disease recurrent Breast angiosarcoma Autoimmune myositis Cutaneous T-cell lymphoma T-cell lymphoma Prolymphocytic leukaemia Fibrosarcoma Immunodeficiency Acquired haemophilia B-cell lymphoma recurrent Meningitis meningococcal Small cell lung cancer Osteogenesis imperfecta Andersen-Tawil syndrome Immunodeficiency congenital More trials…

    Learn about Rare Diseases

    Haemophilia B with anti factor IX – Trials in Disease Myelodysplastic syndrome with excess blasts – Diagnostics Alternating hemiplegia of childhood Haemophagocytic lymphohistiocytosis – Diagnostics Cholangitis sclerosing – Trials in Disease Mantle cell lymphoma refractory – Treatment Pelizaeus-Merzbacher disease – Trials in Disease Pemphigus – Basic Information Phenylketonuria – Diagnostics Chronic granulomatous disease – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Heterodimeric Interleukin-15 Botulinum Toxin Type A Mecasermin Rinfabate Menotrophin Xenon Lisocabtagene Maraleucel Afatinib Sodium 2-Hydroxylinoleate Iomeprol Salbutamol ANGIOTENSIN II Mva-209-Fsp-B1 Io102 Hydrochloride Pegargiminase Xp-Dc+Tl+Klh Belimumab Galcanezumab Azd9550 Tavapadon Clopidogrel More therapies…

    Learn about Your Condition

    Arterial stiffness Obstructive airways disorder Oesophageal food impaction Lymphoedema Skin ulcer Infant sedation External cephalic version Gastrointestinal carcinoma Oropharyngeal cancer Pyoderma Peritoneal abscess Osteoporosis Chondrocalcinosis Hypertonic bladder Uterine cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm

  • Study of Niraparib and Dostarlimab for Children with Recurrent or Hard-to-Treat Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Neoplasm
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    Czechia France Germany Hungary Spain

  • Study on the Safety and Effectiveness of MK-1200 for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Mk-1200
    France Italy Poland Spain

  • Study of Avapritinib for Children with Solid Tumors Linked to KIT or PDGFRA Signaling

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Avapritinib
    Austria France Germany Italy

  • Study of TYRA-300 for Patients with Advanced Bladder Cancer and Other Solid Tumors with FGFR3 Gene Changes

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Transitional cell carcinoma
    • Neoplasm
    Investigated Drugs:
    • Tyra-300-B01
    France Italy Spain

  • Study of Atezolizumab and Tiragolumab for Patients with Resectable Solid Tumors at Intermediate-High Risk of Recurrence

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Atezolizumab
    • Tiragolumab
    Spain

  • Study of AZD5305 Alone and with Other Cancer Drugs for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Neoplasm
    Investigated Drugs:
    • Saruparib
    • Camizestrant
    • Datopotamab Deruxtecan
    Czechia Hungary Italy Poland Spain
Previous Page
1 … 18 19 20 21 22 … 25
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!